Introduction. Patients with cardio-vascular pathology in 90% cases had fatty liver with elements of fibrosis, which directly precedes non-alcoholic steatohepatitis.
Aim. To evaluate the efficiency and safety of the correction of serum lipid spectrum disorders in patients with stable coronary heart disease combined with non-alcoholic steatohepatitis.
Materials and methods. The subject of the study were 51 patients with stable coronary heart disease of II–III functional classes and non-alcoholic steatohepatitis.
Results. Combined use of rosuvastatin at a dose 10 mg/day and omega-3 polyunsaturated fatty acids caused the achievement of a target LDL level <1.8 mmol/L in 13 (76.5%) patients after 3 months of treatment with preserving stable lipid-lowering effect within 6 months in 15 (88.2%) patients vs. rosuvastatin at a dose 10 mg/day, which was accompanied by the achievement of a target level in 15 (71.4%) cases only at the 6th month of therapy and atorvastatin at a dose 20 mg/day, which was characterized by a significant impact on the serum lipids concentration, however, did not achieve their target levels even after 6 months of treatment in patients with stable coronary heart disease combined with non-alcoholic steatohepatitis.
Conclusions. Prescription of a long-term combined hypolipidemic therapy with rosuvastatin at a dose 10 mg/day and omega-3 polyunsaturated fatty acids provide the most effective and steady control of the serum lipid profile in patients with stable coronary heart disease combined with non-alcoholic steatohepatitis.